Back to News
Market Impact: 0.15
Sobi to present clinical data on Gamifant® at Histiocyte Society 2026 in Rotterdam
Source: PR Newswire
Healthcare & BiotechProduct Launches
Sobi will present new clinical data for Gamifant (emapalumab) in primary haemophagocytic lymphohistiocytosis (HLH) at the Histiocyte Society's 2026 annual meeting on September 26-29. The announcement signals continued clinical-development activity for the rare-disease therapy, but provides no efficacy, safety, regulatory, or financial results to assess material valuation impact.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.20
Ticker Sentiment
SOBI0.35
More News
- Eli Lilly’s Foundayo obesity pill eases sleep apnea in late-stage trial, paving way for approval
- Musk says Tesla will refund some Cybertruck deposits, defends decision to end production
- Bon Secours affiliate sweetens bid for Surgery Partners to up to $6 billion
- CorMedix stock gains as Heron deal adds four products
- Rezolute at Guggenheim: FDA progress lifts rare-disease hopes
- Hims & Hers earnings up next: Can GLP-1 boom drive profit?